Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03237923 · ClinicalTrials.gov registry record
Evaluation of the EasySense System in Congestive Heart Failure
A clinical trial of Congestive Heart Failure, sponsored by Ohio State University.
- Completed
- Registry status
- 47
- Enrollment target
- 1
- Study location
NCT03237923 is a study of Congestive Heart Failure that has completed, run by Ohio State University. The registered enrollment target is 47 participants, below the 329-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03237923, a study of Congestive Heart Failure, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The EasySense device is a non-invasive device designed to measure lung fluid in patients with Congestive Heart Failure (CHF). This study seeks to evaluate the efficacy of the EasySense system in measuring lung fluid volume.
Conditions Studied
Interventions
- DEVICE EasySense device
Study Locations (1)
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2020-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03237923
The ClinicalTrials.gov registry entry for NCT03237923 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 329-participant average among 51 other Congestive Heart Failure trials with a reported enrollment target (86% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congestive Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which EasySense device is the first listed.
NCT03237923 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03237923 about?
NCT03237923 is a clinical study titled "Evaluation of the EasySense System in Congestive Heart Failure". The EasySense device is a non-invasive device designed to measure lung fluid in patients with Congestive Heart Failure (CHF). This study seeks to evaluate the efficacy of the EasySense system in measuring lung fluid volume.
What is the current status of trial NCT03237923?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2017-07-01. Estimated completion is 2020-06-30.
What conditions does trial NCT03237923 study?
This clinical trial studies the following conditions: Congestive Heart Failure.
What interventions are being tested in trial NCT03237923?
The interventions under investigation include: EasySense device (DEVICE).
Who is sponsoring clinical trial NCT03237923?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03237923 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congestive Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Palliative Care for People With HF
RECRUITING
-
Circulating Markers for Ischemic Heart Disease
RECRUITING
-
Stress and Congestive Heart Failure
RECRUITING · NA
-
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
RECRUITING · NA
-
Care Transitions App for Patients With Multiple Chronic Conditions
RECRUITING · NA
-
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.